ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
The impact of palliative care consults on deprescribing in palliative cancer patients.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Deprescribing decisions in palliative care: a qualitative meta-synthesis of multi-stakeholder experiences and influencing factors.BMC palliative care · 2026Pooled it
- Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review.Current oncology reports · 2026Pooled it
- Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Antibiotics must be part of end-of-life decisions: a necessary evil?Intensive care medicine · 2026Article
- Approaches to deprescribing cardiovascular medications in patients receiving palliative care: a scoping review.Clinical hypertension · 2026Review
- The impact of palliative care consults on medicines optimisation for patients with cancer referred to hospice care at the end of life: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Impact of the deprescribing timing on medicines optimisation in older cancer patients receiving hospice care at the end of life: a comparative cohort study.European geriatric medicine · 2025Observational
- Pharmacist-led deprescribing interventions for cancer patients in a specialist palliative care setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- Trends in prescriptions and factors associated with discontinuation of potentially inappropriate medications in elderly patients with advanced cancer at the end of life: A retrospective cohort study.Palliative care and social practice · 2025Article
- Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients.Current oncology (Toronto, Ont.) · 2023Review
- Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Cultures that collide: an ethnographic study of the introduction of a palliative care consultation team on acute wards.BMC palliative care · 2021Article
- Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review.Exploratory research in clinical and social pharmacy · 2021Article
- Deprescribing practices in Canada: A scoping review.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe transition from active cancer treatment to palliative care often results in a shift in drug risk-benefit assessment which requires the deprescribing of various medications. Deprescribing in palliative cancer patients can benefit patients by reducing their pill burden, decrease potential side effects, and potentially decrease healthcare costs. In addition, a change in patients' goals of care (GOC) necessitates the alteration of drug therapy which includes both deprescribing and the addition of medications intended to improve quality of life. Depending on a patient's GOC, a medication can be considered as inappropriate.
objectivesPrimary: Comparison between potentially inappropriate medications (PIMs) prior to the palliative care consult (PCC) versus after the PCC. Secondary: Association between PIMs and GOC.
methodsThe study was a 1-year retrospective database review. The study included cancer patients seen by the PCC team at the University of Alberta Hospital. The OncPal guidelines were used to identify and determine the number of PIMs prior to the PCC and after the PCC.
resultsThe reduction in PIMs prior to PCC versus after the PCC was statistically significant (p value < 0.001), demonstrating the PCC has a positive significant impact on deprescribing PIMs. For our secondary outcome, an overall decrease in PIMs was observed with the changes of GOC. The strength of the correlations was low (r < 0.1), and the p value was 0.056.
conclusionThis study shows the positive impact a PCC has on deprescribing and reveals the importance of using guidelines for deprescribing in palliative cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.